JPRN-UMIN000012218招募中未知
A phase I study of conbination therapy with intratumorak administration of dendritic cells and radiation for far advanced esophageal cancer - Chiba RT-DC therapy
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1. History of radiotherapy or immunotherapy 2. tumor has fistula 3. obvious infection 4. hypoalbuminemia 5. uncontrorable pleural effusion or ascites 6. severe heart failure 7. other complications (ileus, pneumonitis, pleural fibrosis, DM, renal failure, liver cirrhosis) 8. Psychologic diorders 9. double cancers 10. steroid administration
研究者
相似试验
已完成
2 期
Phase II study of combination therapy with Irinotecan and S-1 in patients with progressive colorectal cancer after FOLFOX regimenresectable advanced/recurrent colorectal cancerJPRN-UMIN000001342KSCC56
已完成
不适用
The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancerJPRN-UMIN000013378Kyoto Prefectural University of Medicine9
尚未招募
不适用
A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancercolonrectal cancerJPRN-UMIN000004659The University of Tokushima Graduate School35
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
